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Abstract
Background: Delay in implementing new treatments into clinical practice results in considerable health and economic
opportunity costs. Data from the UK TOBY Cooling Register provides the opportunity to examine how one new effective
therapy for newborn infants suspected of suffering asphyxial encephalopathy – therapeutic hypothermia- was implemented
in the UK.
Methodology/Principal Findings:We analysed returned data forms from inception of the Register in December 2006 to the
end of July 2011. Data forms were received for 1384 (67%) of the 2069 infants registered. The monthly rate of notifications
increased from median {IQR} 18 {15–31} to 33 {30–39} after the announcement of the results of the recent TOBY trial, and to
50 {36–55} after their publication. This rate further increased to 70 {64–83} following official endorsement of the therapy,
and is now close to the expected numbers of eligible infants. Cooling was started at 3.3 {1.5–5.5} hours after birth and the
time taken to achieve the target 33–34uC rectal temperature was 1 {0–3} hours. The rectal temperature was in the target
range in 83% of measurements. From 2006 to 2011 there was evidence of extension of treatment to slightly less severely
affected infants. 278 of 1362 (20%) infants died at 2.9 {1.4–4.1} days of age. The rates of death fell slightly over the period of
the Register and, at two years of age cerebral palsy was diagnosed in 22% of infants; half of these were spastic bilateral.
Factors independently associated with adverse outcome were clinical seizures prior to cooling (p,0.001) and severely
abnormal amplitude integrated EEG (p,0.001).
Conclusions/Significance: Therapeutic hypothermia was implemented appropriately within the UK, with significant benefit
to patients and the health economy. This may be due in part to participation by neonatal units in clinical trials, the
establishment of the national Register, and its endorsement by advisory bodies.
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Introduction
Delay in implementing new treatments into clinical practice
once the evidence base has been established was identified as a
‘gap in translation’ by Sir David Cooksey in his review of UK
Health Research, and results in considerable health and economic
opportunity costs. [1] Data from the UK TOBY Cooling Register
provides the opportunity to examine how one new effective
therapy for newborn infants suspected of suffering asphyxial
encephalopathy – therapeutic hypothermia- was implemented in
the UK.
Extensive experimental and clinical research has been carried
out into prolonged moderate hypothermia for perinatal asphyxial
encephalopathy.[2–9] Synthesis of the results of randomised
controlled trials show that the number needed to treat (NNT)
with cooling to prevent one additional death or disabled survivor is
7, 95% confidence interval (CI) 4–14. [10,11] Although reports
from single institutions indicate that therapeutic hypothermia is
increasingly used, so far there has been no report of national
uptake of this therapy.
The UK TOBY Cooling Register was set up immediately
following the conclusion of enrolment to the TOBY trial
(ISRCTN8954757) a multicentre randomised controlled trial of
whole body hypothermia for the treatment of perinatal asphyxial
encephalopathy, supported by the Medical Research Council,
UK, and predominantly carried out in the UK. [4] The objectives
of the UK TOBY Cooling Register were to: provide guidance to
clinicians considering the introduction of this therapy; audit the
uptake and conduct of therapeutic hypothermia in the UK; and to
undertake surveillance for adverse effects related to cooling. The
UK TOBY Cooling Register became operational in December
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2006 and since then all newborns treated with cooling in the UK
have been eligible to be registered.
When the results of the TOBY trial together with the other trials
confirmed the therapeutic efficacy of prolonged moderate cooling,
the TOBY study group planned the systematic implementation of
cooling therapy throughout the UK. Register personnel produced
a clinical protocol and handbook, and delivered a programme of
presentations about therapeutic hypothermia to UK Neonatal
Networks and at study days throughout the country. These
supported the organisation of local services for the provision of
hypothermia and the development of local clinical protocols.
Subsequently, the introduction of cooling therapy into clinical
practice and the reporting of cases to the Register were endorsed
by the UK National Institute for Heath and Clinical Excellence
(NICE) and the British Association of Perinatal Medicine. [12,13].
Based on previous UK population studies [14,15], the
prevalence of moderate to severe perinatal asphyxial encephalop-
athy is estimated to be 1–1.5/1000 births, and with a term birth
rate of about 750,000 births [16], the number of infants that would
be eligible for therapeutic hypothermia is estimated to be 750–
1125 infants annually. This study aimed to determine whether
there had been a ‘gap in translation’ in the implementation of
therapeutic hypothermia, by: analysing the uptake of therapeutic
hypothermia in the UK in relation to the developing evidence
base; comparing the number of notifications with the expected
health service provision needs; examining compliance with
recruitment and treatment guidelines; and scrutinising the clinical
characteristics and outcomes of treated infants relative to patients
enrolled in the clinical trials.
Methods
The UK TOBY Cooling Register
The UK TOBY Cooling Register has been briefly described
before [17], and the guidance and data forms are publicly
available from the Register website: www.npeu.ox.ac.uk/
tobyregister. The Register is located at the National Perinatal
Epidemiology Unit (NPEU), Oxford, UK. It is managed by a co-
ordinator (BS) and a clinical supervisor (DA), together with core
personnel within the NPEU. Initial financial support for 12
months was provided by the UK Neonatal Task Force. The
Register collects information about any newborn who receives
treatment with cooling in the UK including Northern Ireland
whether or not this was delivered according to the Register clinical
protocol and guidelines, although there is no statutory obligation
to register cases. All notified cases are allocated a unique patient
identification number but no patient identifiers are collected, so
consent from the parents for data collection is not required.
The Register handbook gives guidance on which infants should
be considered for treatment with cooling, with the aim to start
Figure 1. UK TOBY Cooling Register: number of registrations and cooling centres by month. The horizontal lines indicate the range of
expected eligible cases in the UK.
doi:10.1371/journal.pone.0038504.g001
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cooling within six hours of birth. The indications are based on the
criteria used in the TOBY trial, namely the presence in infants of
at least 36 weeks gestation, of evidence of perinatal asphyxia
together with signs of moderate or severe encephalopathy. Unlike
in the TOBY trial, an abnormal amplitude integrated EEG
(aEEG) recording is not a mandatory requirement, although
clinicians are advised to perform aEEG recording whenever
possible. This change from the TOBY trial was made primarily to
avoid delay in initiating treatment with cooling when the aEEG is
not available at the place of birth. The observation that patient
characteristics and outcomes were similar amongst the randomised
trials, yet only some included an abnormal aEEG as a trial entry
criterion, suggests that it need not be a mandatory requirement.
Centres that introduce treatment with cooling are asked to
nominate a lead contact person. An information pack about the
Register and training material are provided and the Register co-
ordinator provides specific guidance as required. Details of the
neonatal centres notifying cases to the Register are available on the
Register website. A monthly reminder note asking for a list of cases
cooled in that month is sent to each registered cooling centre.
Cases can be notified to the Register by telephone or email and
this can be done retrospectively.
Clinical and treatment details are collected on a specific data
record form that can be downloaded from the Register website.
When the infant is approaching 2 years of age a request is sent to
the notifying clinician asking for details of clinical outcomes at 2
years using a further downloadable record form; currently in the
UK there is no statutory requirement for follow-up of infants who
suffered neonatal encephalopathy or who received therapeutic
hypothermia. Details sought are the findings on neurological
examination, an assessment of neuromotor function using the
Gross Motor Function Classification System (GMFCS) [18] and
the Manual Abilities Classification System (MACS) [19] and the
results of a neurodevelopmental assessment. The neurodevelop-
mental tests most commonly used in the UK are the Griffiths
Mental Scales (Hogrefe Ltd, Oxford, England) and the Bayley
Scales of Infant and Toddler Development (Pearson Assessment,
London, England).
A chart of each infant’s temperature record is sent back to
notifying clinicians if requested, following receipt of the data
record forms and summary information about their cases is
available to all registered cooling centres. Notification, use of
Register material, feedback service and online and telephone
support are provided freely to all clinicians and the entire Register
website is publicly accessible.
The numbers of hospitals registering their first case is shown in
Figure 2. Only those hospitals that participated in the TOBY trial
registered cases in the first 18 months after inception of the
Register; other hospitals began registering cases after the TOBY
trial results became available. Figure 3 shows the distribution of
cooling centres in the UK. Three centres from Eire contributed
data from 35 cases. Of 74 UK neonatal units that notified the
Register of the intention to provide therapeutic hypothermia, 54
were classed Level 3 (highest level of care) units, 11 were classed
Level 2 units; the level of care was indeterminate in the remaining
9 units. The median {IQR} number of infants cooled in each unit
were 29 {20–52} in Level 3 neonatal units and 3 {0–11} in the
Level 2 neonatal units.
Statistical Methods
We analysed returned data forms from inception of the Register
in December 2006 to the end of July 2011. We report the
individual and cumulative number of notifications and treatment
centres contributing to the Register. Numbers (with percentages)
are presented for binary and categorical variables, and means
Figure 2. Number of hospitals registering first case in 6 month periods from inception of Register. Shaded bars indicate hospitals that
participated in the TOBY trial and clear bars hospitals that did not participate in the TOBY trial.
doi:10.1371/journal.pone.0038504.g002
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(with standard deviations) or medians (with lower and upper
quartiles ({IQR}) for continuous variables as appropriate.
We used poisson regression to examine the difference in the rate
of monthly registrations 6 months before and the 6 months after
the results of the TOBY trial became available, their publication
and the publication of the NICE guidelines. We analysed the
temperature profiles and clinical details of notified cases, including
severity of encephalopathy assessed by a modification of the
Sarnat score [3] or by the Thompson score [20], and outcome at
discharge and at 2 years of age. We examined trends in clinical
characteristics over time using the Chi-squared test for trend for
categorical variables and the non parametric test for trend for
ordinal and continuous variables. [21]
We investigated risk factors for adverse outcome at 2 years for
those with available outcome data. Adverse outcome at 2 years
was defined as death, cerebral palsy and/or a GMFCS or MACS
score .2. First we examined the association of the following risk
factors with adverse outcome in a bivariate analysis using Fisher’s
exact test: clinical seizures prior to cooling, the aEEG, Apgar score
at 10 minutes, cord gas pH, base excess and Thompson
encephalopathy score prior to cooling. Significant factors in the
bivariate analysis (p value,0.05) were included in a multivariate
logistic regression analysis.
Two-sided 5% significance tests and 95% confidence intervals
are reported throughout. Stata/SE version 11.1 was used for all
data analysis.
Ethics and Consent
The UK Central Office for Research Ethics Committees
advised that Research Ethics Committee review was not required
as the Register was considered a service evaluation. Subsequently
the UK National Research Service also advised that since no
patient identifiers are collected there is no statutory requirement
for consent from the parents for data collection and consent was
not sought. The Register guidelines advise clinicians to discuss
offering treatment with cooling with the parents and to follow local
practice as to whether formal consent for treatment should be
sought, but we did not collect this information from registering
centres.
Figure 3. Distribution of cooling centres in the UK. Three centres from Eire contributed data from 35 cases and these are included in this
report.
doi:10.1371/journal.pone.0038504.g003
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Results
2069 notifications were received by the end of July 2011.
Figure 1 shows the monthly and cumulative registrations and
contributing hospitals since inception of the Register. The monthly
rate of notifications increased from median {IQR} 18 {15–31} in
the 6 month period before the announcement of the results of the
TOBY trial in November 2008, 33 {30–39} in the 6 months
before the publication of the TOBY trial results in October 2009
and 50 {36–55} in the following 6 months; the rate of registrations
increased further in the 6 months following publication of the
NICE endorsement of therapeutic hypothermia in May 2010
when a median {IQR} 70 {64–83} infants monthly were notified
to the Register. Since then, the monthly rate of notifications has
remained fairly steady at a median {IQR} of 68 {62–82}.
Clinical characteristics after birth were consistent with moder-
ate/severe asphyxial injury in most cases (Figure 6). Of 513 infants
with completed Thompson encephalopathy scores prior to
initiation of cooling, with lower scores indicating milder enceph-
alopathy, 91 infants (18%) scored 0–5, 265 infants (51%) scored 6–
12, and 157 infants (31%) scored .12.
Clinical Characteristics
At the time of data analysis in July 2011, data forms had been
received for 1384 (67%) of the 2069 infants registered and the key
clinical characteristics of these infants are shown in Table 1.
Figure 4. Frequencies of age at start of cooling in hours after birth.
doi:10.1371/journal.pone.0038504.g004
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In 1331 cases with data available, cooling was started at a
median {IQR} of 3.3 {1.5–5.5} hours after birth and the time to
achieve the target 33–34uC rectal temperature was a median
{IQR} of 1 {0–3} hours. The distribution of the age in hours at
start of cooling is shown in Figure 4. For 29/1331 (2.2%) infants,
cooling was commenced more than 12 hours after birth. The
method of cooling was whole body cooling in all but 3 cases; servo
controlled equipment was used in half the cases during the last 12
months. The mean hourly rectal temperature from the start of
cooling is shown in Figure 5. The rectal temperature was in the
target range in 83% of 79,584 measurements recorded during the
maintenance phase of cooling from 8 to 72 hours. Excessive
cooling to below 33uC occurred in 887/1368 (65%) infants at
some point, but this was mostly in the 32–33uC range. The rectal
temperature was below 31uC at some point in 61/1368 (4%) of
infants.
The proportion of infants with suspected clinical seizures before
cooling started decreased over the time period of the Register
(Figure 6). Similarly the proportion of infants with a severely
abnormal aEEG grade reported prior to cooling decreased over
time. There was also an improvement in Apgar scores at 10
minutes and first blood base excess from 2007 to 2011. In the last
12 month period, the proportion of infants with seizures before
cooling started was 49.2% (95% CI 43.5% to 54.9%); the
proportion with a severely abnormal aEEG was 34.0% (95% CI
28.5% to 39.9%); the median {IQR} Apgar scores at 10 minutes
were 5 {3 to 7}; and the base excess median {IQR} 217.1
{221.0 to 213.3}.
Among 1121 babies with data recorded over the first four days,
the proportion of infants with suspected clinical or aEEG seizures
progressively fell from 62% at 24 hours of age to 13% on the 4th
day after birth. There was a similar progressive improvement in
the encephalopathy score during the same period. Among 1384
infants, respiratory support with mechanical ventilation or
continuous positive airways pressure was required in 1144 (82%)
on day 1, 842 (61%) on day 2, 673 (49%) on day 3 and 466 (34%)
on day 4.
Thirty eight of 1350 (2.8%) cases were born before 36 weeks
gestation; 4 were born at 34 weeks and the others were born at 35
weeks. The median Apgar scores were 1, 4 and 5 at 1, 5 and 10
minutes and the median pH and base excess were 6.82 and
219.1 mmol/L in the cord blood or first blood sample after birth.
Suspected seizures occurred in 17/33 (52%) before cooling was
started and placental abruption was reported in 18/38 (47%)
cases.
Adverse Events (Table 2)
Potential adverse events during the first four days after birth that
were included in the Register data forms are shown in table 2, and
the frequency of key clinical conditions during the hospital
admission period is shown in table 3.
We have recently reported the occurrence of subcutaneous fat
necrosis in approximately 1% of registered infants. [22] Three
cases of inadvertent excessive cooling due to malfunction of
equipment caused by a broken temperature probe were notified
and these incidents were reported to the Medical Devices Agency
(UK). Other unusual events included the occurrence of one case of
vitreous haemorrhage, with full recovery; hearing loss in 2/7
children from one centre where aminoglycosides were routinely
administered; a case of collapse associated with severe unexplained
hypertension after rewarming, again with full recovery; and
reports of severe bradycardia following lidocaine infusion, which
prompted reinforcement of the guidance to reduce infusion rates
and duration during cooling.
Outcomes at Discharge
Of 1362 infants with known outcomes during the first hospital
admission, 278 (20%) died before discharge at a median {IQR} of
2.9 {1.4 to 4.1} days of age and 172 (13%) were transferred to a
different hospital (Table 1). The mortality rate decreased from 24/
109 (22%) in 2007 to 17/117 (15%) in 2011, Chi-squared for trend
P= 0.08, but there may be a time lag in the notification of deaths
in the current year. Full enteral feeding was achieved by 777/1046
Figure 5. Mean hourly rectal temperature from the start of cooling to 96 hours of age.
doi:10.1371/journal.pone.0038504.g005
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Figure 6. Clinical characteristics by year of registration.
doi:10.1371/journal.pone.0038504.g006
Table 1. Key clinical characteristics of infants notified to the UK TOBY Cooling Register from December 2006 to July 2011.
Characteristic n=1384
Gestational age at birth, weeks (n = 1350)
Median {IQR} 40 {38.4 to 41.1}
[Range] [34.0 to 44.4]
Birth weight, grams (n = 1379)
Median {IQR} 3340 {2900 to 3800}
[Range] [1530 to 5830]
Age when cooling commenced, hours (n = 1331)
Median {IQR} 3.3 {1.5 to 5.5}
[Range] [0 to 35.3]
Cooling commenced after 12 hours of age, n (%) (n = 1331) 29 (2.2)
Cooled before gestational age of 36 weeks, n (%) (n = 1348) 38 (2.8)
Outcome at discharge, n (%) (n = 1362)
Discharged home 912 (67)
Transferred to a different hospital 172 (13)
Died before discharge 278 (20)
doi:10.1371/journal.pone.0038504.t001
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(74%) of survivors before discharge at a median {IQR} age of 8 {6
to 12} days; this did not alter significantly during the study period.
Among infants born before 36 weeks gestation, 12 (32%) infants
died at a median {IQR} of 2.5 {1.7 to 4.2} days of age, and 17/24
(71%) of survivors achieved full enteral feeding before discharge at
a median {IQR} of 14 {8 to 17} days.
Outcomes at 2 Years
Outcome data at 2 years of age were received from 275/574
(48%) of requests (Table 4). There were no significant differences
in the clinical characteristics, aEEG prior to cooling, and the age
in hours after birth when cooling was started between the infants
with or without 2 year outcome data available. Cerebral palsy was
clinically diagnosed in 56/251 (22%) infants and half of these were
spastic bilateral involving 4 limbs. Levels 3–5 (indicating severe
neuromotor disability) were recorded in 27/51 (53%) infants with
cerebral palsy assessed with the GMFCS and in 29/51 (57%)
infants assessed with the MACS.
Formal neurodevelopmental assessment was carried out in 135/
249 (54%) of cases, but a developmental quotient was only
obtained in 34 cases; in the other children it could not be obtained
or the forms were incomplete, so it was not possible to explore
factors associated with neurodevelopmental outcome. A further 8/
275 (3%) died following discharge from hospital and before 2
years.
Risk factors significantly associated with adverse outcome at 2
years in the bivariate analyses were: clinical seizures prior to
cooling, severely abnormal aEEG, Apgar score at 10 minutes, base
excess and Thompson encephalopathy score prior to cooling. The
Thompson encephalopathy score was not included in the
multivariate model because the score was only available for 70
babies with 2 year outcome data. In the multivariate analysis of
adverse outcome (n= 149), the factors that were independently
associated with adverse outcome were clinical seizures prior to
cooling (p,0.001) and severely abnormal aEEG (p,0.001).
Discussion
Intervention with moderate cooling for neural rescue in
newborns with hypoxic-ischaemic brain injury is the culmination
of a series of research studies spanning decades. These proved the
potential for neural rescue following perinatal asphyxia [23];
consistently showed benefit from post-insult cooling in appropriate
experimental models [24,25]; examined safety and feasibility in
preliminary clinical studies [26,27]; and confirmed efficacy by
synthesis of the results of several well conducted randomised
clinical trials in newborns [10].
The UK TOBY Cooling Register data indicate that there has
been timely, systematic implementation of therapeutic hypother-
mia in the UK to a standard protocol, so successfully bridging the
‘gap in translation’ from research to clinical use. [1] From the
inception of the Register there was a steady rise in the number of
notifications that intensified once the results of the TOBY trial
were announced, and increased further following official endorse-
ment of this therapy.
Because of a lack of systematic recording, the incidence of
neonatal encephalopathy in the UK is uncertain as are the
outcomes following encephalopathy. The current rate of notifica-
tions to the UK TOBY Cooling Register is very close to our
estimate that 750–1125 infants annually would be eligible for
therapeutic hypothermia based on previous UK population studies
and the term birth rate. We suggest that the rapid uptake and now
consistently high rate of provision of therapeutic hypothermia was
aided by two factors. First, several UK neonatal centres
participated in the TOBY trial and so were ready to implement
therapeutic hypothermia into clinical practice; this highlights the
value to a healthcare system of active participation in clinical trials.
Second, the guidance and the clinical feedback provided nationally
by the Register, which demonstrates the value to patients and the
Table 2. Adverse events on days 1–4 after birth reported to
the UK TOBY Cooling Register (Number of forms with
completed data: 1384).
Event Frequency (%)
Sepsis 232 (17)
Hypoglycaemia 344 (25)
Hypotension 557 (40)
Coagulopathy 435 (31)
Arrhythmia 118 (9)
Definitions:
Sepsis: Any evidence of infection requiring antibiotic therapy which is
confirmed on culture.
Hypoglycaemia: Blood glucose below 2.6 mmol/litre.
Hypotension: Persistent mean blood pressure of ,40 mmHg.
Coagulopathy: Any disorder requiring treatment in order to maintain or recover
normal haemostasis.
Arrhythmia: Sinus bradycardia below 80 beats per minute and other
arrhythmias identified on the electrocardiogram.
doi:10.1371/journal.pone.0038504.t002
Table 3. Key clinical diagnoses reported to the UK Toby
Cooling Register during hospital admission (Number of forms
with completed data = 1384).
Event Frequency (%)
Meconium aspiration 144 (10)
Pulmonary haemorrhage 41 (3)
Pulmonary hypertension 99 (7)
Pulmonary airleak 63 (5)
Pneumonia 20 (1)
Late onset sepsis 30 (2)
Renal failure treated with dialysis 8 (0.6)
Necrotising enterocolitis 9 (0.7)
Major cerebral anomaly on cranial
ultrasound
38 (3)
Definitions:
Meconium aspiration: The presence of meconium stained liquor at birth and
severe respiratory distress within 1 hour of birth and compatible X-ray changes.
Pulmonary haemorrhage: Copious bloody secretions with clinical deterioration
requiring change(s) in ventilatory management.
Pulmonary hypertension: Severe hypoxaemia disproportionate to the severity
of lung disease and evidence of a right to left shunt.
Pulmonary airleak: Any radiologically confirmed airleak serious enough to affect
management (including pneumothorax, pulmonary interstitial emphysema,
pneumopericardium, pneumoperitoneum and pneumomediastinum).
Late onset sepsis: Any evidence of infection after 72 hours from birth requiring
antibiotic therapy which is confirmed on culture.
Necrotising enterocolitis: Infants with abdominal distension, gastric aspirate
and/or blood in stools together with abdominal X-ray showing bowel oedema,
pneumatosis or pneumoperitoneum, i.e. Bell’s staging 2 or 3.
Major cerebral anomaly on cranial ultrasound: Including evidence of
parenchymal haemorrhage as determined by ultrasound, ventricular dilatation
(defined as .97th centile for gestational age) or the presence of porencephalic
cysts or cystic leukomalacia.
doi:10.1371/journal.pone.0038504.t003
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UK Health Economy of continued research and development
funding following the completion of pragmatic trials.
In a meta analysis of the clinical trials of cooling the mortality
rate in the cooled groups was 25% and the rate of disabling
cerebral palsy was 21% in survivors, which are very similar to our
data from infants reported to the national Register of therapeutic
hypothermia in the UK. [10] Since treatment with cooling for 72
hours cooling is cost saving by 18 months of age, it is likely to have
important benefits to the health economy in countries where the
intervention is applied widely. [28] From the number of infants
treated with cooling since the inception of the Register and the
NNT of 7 infants to prevent one additional disabled survivor
reported from the clinical trials, using current lifetime costs for
each child with cerebral palsy (about £750,000) [29] and the
economic benefit of additional healthy lives (about £800,000) [30],
the total benefit to the UK economy as a result of the
implementation of therapeutic hypothermia is likely to be in
excess of £125 million so far.
In the absence of any specific therapy for a devastating
condition, and following encouraging if not definitive results of
two previous randomised controlled trials [31], when recruitment
for the TOBY trial was complete many clinicians wished to offer
therapeutic hypothermia on compassionate grounds before the
procedure had been assessed by the regulatory authorities.
Therapeutic hypothermia was first notified to NICE before the
results of the TOBY trial were available, so the review process was
postponed until publication of the trial results. The UK TOBY
Cooling Register was ideally placed to support those clinicians that
wished to offer therapeutic hypothermia whilst also providing
specialist advice to the NICE review process so that a co-ordinated
approach to implementing this therapy was achieved.
An initial concern expressed by regulatory authorities and
specialist bodies is that therapeutic hypothermia may be applied
outside the criteria used in the clinical trials- that is a ‘therapeutic
drift’ to treatment with cooling in less severely affected newborns
or in conditions other than suspected perinatal asphyxia enceph-
alopathy. [12,13] Indeed, the clinical condition at birth improved,
and the percentage of infants with clinical seizures before cooling
reduced over the period of the Register (Figure 6); however, the
clinical characteristics of registrants in the last 12 month period of
the Register remained consistent with treatment guidelines.
It is to be expected that outside a clinical trial, clinicians will
explore therapeutic options more widely on compassionate
grounds. For any therapy, clinicians must consider how applicable
the supporting evidence is to the individual case, the risk of side
effects and the availability of other treatments; it is not sufficient to
rely solely on the eligibility criteria of clinical trials, and clinicians
may opt to treat patients that differ in some respects from those
entered in the clinical trials. [32,33] The UK TOBY Cooling
Register guidelines provide advice on the use of cooling outside
clinical trial criteria such as after 6 hours from birth or in infants
born before 36 weeks gestation or after presumed postnatal
hypoxic-ischaemic acute events. The gestational age was the same
as in the TOBY trial ( =.36 weeks gestation) in all but 3% of
registrants, and the lowest gestation reported was 34 weeks. The
mortality rate in the infants born before 36 weeks gestation was
greater than in the whole group, 12/38 (30%) compared with
278/1362 (20%); this observation may be due to selection bias but
it highlights the need to critically assess the extension of
therapeutic hypothermia to premature infants. Overall these data
suggest that only minor ‘therapeutic drift’ occurred over the
duration of the Register but continued surveillance is important.
It has been suggested that the severity of encephalopathy
assessed clinically or by aEEG is less predictive of subsequent
outcome when infants are treated with hypothermia. [34–36]
However, in another study of infants treated with hypothermia,
severe encephalopathy and an abnormal aEEG were related to
outcome at 18 months of age. [37] Register data suggest that in
addition to the severity of encephalopathy and the aEEG, the
occurrence of clinical seizures prior to cooling is also a risk factor
for adverse outcome at 2 years of age. These clinical features may
identify a group of infants who might benefit by earlier institution
of therapeutic hypothermia or who may be candidates for studies
of additional neuroprotective therapies. Experimental studies
support the concept that the ‘therapeutic window’ is shorter and
hypothermia needs to be started earlier in more severely affected
infants. [38].
Adverse events, such as biochemical and metabolic abnormal-
ities and coagulopathy were frequent during the first four days
after birth but it is likely that these were due to the severity of
perinatal asphyxia rather than treatment with cooling. Culture
proven sepsis was reported in 17% of cases in the first 72 hours
following birth, and occurred in just 30/1384 (2%) after the end of
cooling, suggesting that sepsis was unlikely to be related to
treatment with cooling. Pneumonia has been associated with
therapeutic hypothermia in adult studies but this complication was
reported in less than 2% of cases notified to the Register. Apart
from subcutaneous fat necrosis, which was reported in approxi-
mately 1% of cases, other adverse conditions occurred with a
similar frequency to that reported in the clinical trials.
There are a number of limitations to the analysis of data from
registers, such as: difficulty in ascertaining uptake of registration
especially when the incidence of the disorder is not known;
reporting bias; and incomplete or erroneous data. Therefore,
caution is necessary when interpreting the data especially when
Table 4. Two year outcomes of infants notified to the UK
TOBY Cooling Register (Number forms with completed data
= 275).
Outcome n (%)
Gross Motor Function Classification System (GMFCS), (n = 65)*
Level 1–2 38 (58)
Level 3–5 27 (42)
Manual Ability Classification System (MACS), (n = 65)*
Level 1–2 36 (55)
Level 3–5 29 (45)
Cerebral palsy (n = 251) 56 (22)
Bilateral 2 limb 4 (2)
Bilateral 4 limb 29 (12)
Hemiplegic left 6 (2)
Hemiplegic right 3 (1)
Dystonic 5 (2)
Choreoathetoid 1 (–)
Ataxic 3 (1)
Non-classifiable 5 (2)
Occipital head circumference (cm), (n = 196)
Mean (SD) 48 (2.5 )
*15 children with GMFCS/MACS levels 1–2 were recorded as not having cerebral
palsy and 5 children recorded as having cerebral palsy were not classified using
these scales.
doi:10.1371/journal.pone.0038504.t004
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comparing outcomes with those reported in clinical trials or with
historical data. However, registers are ideal for monitoring
practices and patient outcomes outside the narrow context of
clinical trials. The UK TOBY Cooling Register was set up
specifically to monitor the introduction of therapeutic hypother-
mia in the UK in infants with perinatal asphyxial encephalopathy.
Registration of cases is entirely voluntary; we aimed to encourage
participation in the Register by providing clinical guidance
including individual advice if required, specific data forms that
could be used as part of the clinical record and clinician feedback.
The number of notifications during the last 12 months of the
Register was close to the estimated number of infants eligible for
treatment, which suggests that our data provide a representative
account of the use of this therapy in the UK.
The Register data show that in the UK most infants are treated
safely and appropriately, according to treatment criteria, within 6
hours of birth, with good temperature control and few complica-
tions related to cooling. The rates of death and severe disability are
similar to those reported in the randomised controlled trials of
hypothermia. These data indicate that therapeutic hypothermia
was implemented appropriately within the UK, with significant
benefit to patients and the UK health economy. This may be due
in part to participation by UK neonatal units in clinical trials, the
establishment of the national Register, and its endorsement by
national advisory bodies.
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